Structure, heterogeneity and developability assessment of therapeutic antibodies

References

• Lavoisier A, Schlaeppi JM. Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection. MAbs. 2015;7:77–83. doi:10.4161/19420862.2014.985544.
   PubMed Web of Science ®Google Scholar
• Dobson CL, Devine PW, Phillips JJ, Higazi DR, Lloyd C, Popovic B, Arnold J, Buchanan A, Lewis A, Goodman J, et al. Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo. Sci Rep. 2016;6:38644. doi:10.1038/srep38644.
   PubMed Web of Science ®Google Scholar
• Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs. 2013;5:787–794. doi:10.4161/mabs.25269.
   PubMed Web of Science ®Google Scholar
• Strohl WR. Current progress in innovative engineered antibodies. Protein Cell. 2018;9:86–120. doi:10.1007/s13238-017-0457-8.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat Rev Drug Discov. 2018;17:197–223. doi:10.1038/nrd.2017.227.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Reichert JM. Antibodies to watch in 2018. MAbs. 2018;10:183–203. doi:10.1080/19420862.2018.1415671.
   PubMed Web of Science ®Google Scholar
• Goyon A, D’Atri V, Colas O, Fekete S, Beck A, Guillarme D. Characterization of 30 therapeutic antibodies and related products by size exclusion chromatography: feasibility assessment for future mass spectrometry hyphenation. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1065–1066:35–43. doi:10.1016/j.jchromb.2017.09.027.
   PubMed Web of Science ®Google Scholar
• Yang R, Jain T, Lynaugh H, Nobrega RP, Lu X, Boland T, Burnina I, Sun T, Caffry I, Brown M, et al. Rapid assessment of oxidation via middle-down LCMS correlates with methionine side-chain solvent-accessible surface area for 121 clinical stage monoclonal antibodies. MAbs. 2017;9:646–653. doi:10.1080/19420862.2017.1290753.
   PubMed Web of Science ®Google Scholar
• Goyon A, Excoffier M, Janin-Bussat MC, Bobaly B, Fekete S, Guillarme D, Beck A. Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1065–1066:119–128. doi:10.1016/j.jchromb.2017.09.033.
   PubMed Web of Science ®Google Scholar
• Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. MAbs. 2012;4:385–391. doi:10.4161/mabs.19868.
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–312. doi:10.1038/nbt.1839.
   PubMed Web of Science ®Google Scholar
• Maeda E, Kita S, Kinoshita M, Urakami K, Hayakawa T, Kakehi K. Analysis of nonhuman N-glycans as the minor constituents in recombinant monoclonal antibody pharmaceuticals. Anal Chem. 2012;84:2373–2379. doi:10.1021/ac300234a.
   PubMed Web of Science ®Google Scholar
• Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics. 2008;8:2858–2871. doi:10.1002/pmic.200700968.
   PubMed Web of Science ®Google Scholar
• Kamoda S, Ishikawa R, Kakehi K. Capillary electrophoresis with laser-induced fluorescence detection for detailed studies on N-linked oligosaccharide profile of therapeutic recombinant monoclonal antibodies. J Chromatogr A. 2006;1133:332–339. doi:10.1016/j.chroma.2006.08.028.
   PubMed Web of Science ®Google Scholar
• Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem. 2007;364:8–18. doi:10.1016/j.ab.2007.01.023.
   PubMed Web of Science ®Google Scholar
• Giorgetti J, D’Atri V, Canonge J, Lechner A, Guillarme D, Colas O, Wagner-Rousset E, Beck A, Leize-Wagner E, François Y-N. Monoclonal antibody N-glycosylation profiling using capillary electrophoresis - Mass spectrometry: assessment and method validation. Talanta. 2018;178:530–537. doi:10.1016/j.talanta.2017.09.083.
   PubMed Web of Science ®Google Scholar
• Sydow JF, Lipsmeier F, Larraillet V, Hilger M, Mautz B, Mølhøj M, Kuentzer J, Klostermann S, Schoch J, Voelger HR, et al. Structure-based prediction of asparagine and aspartate degradation sites in antibody variable regions. PLoS One. 2014;9:e100736. doi:10.1371/journal.pone.0100736.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol. 2009;391:404–413. doi:10.1016/j.jmb.2009.06.028.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 2009;106:11937–11942. doi:10.1073/pnas.0904191106.
   PubMed Web of Science ®Google Scholar
• Grebenau RC, Goldenberg DM, Chang CH, Koch GA, Gold DV, Kunz A, Hansen HJ. Microheterogeneity of a purified IgG1 due to asymmetric Fab glycosylation. Mol Immunol. 1992;29:751–758.
   PubMed Web of Science ®Google Scholar
• Lee CC, Perchiacca JM, Tessier PM. Toward aggregation-resistant antibodies by design. Trends Biotechnol. 2013;31:612–620. doi:10.1016/j.tibtech.2013.07.002.
   PubMed Web of Science ®Google Scholar
• Perchiacca JM, Tessier PM. Engineering aggregation-resistant antibodies. Annu Rev Chem Biomol Eng. 2012;3:263–286. doi:10.1146/annurev-chembioeng-062011-081052.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs. 2016;8:1269–1275. doi:10.1080/19420862.2016.1208330.
   PubMed Web of Science ®Google Scholar
• Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112:5997–6002. doi:10.1073/pnas.1408766112.
   PubMed Web of Science ®Google Scholar
• Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104:1885–1898. doi:10.1002/jps.24430.
   PubMed Web of Science ®Google Scholar
• Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111:18601–18606. doi:10.1073/pnas.1421779112.
   PubMed Web of Science ®Google Scholar
• Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012;101:102–115. doi:10.1002/jps.22758.
   PubMed Web of Science ®Google Scholar
• Yang Y, Velayudhan A, Thornhill NF, Farid SS. Multi-criteria manufacturability indices for ranking high-concentration monoclonal antibody formulations. Biotechnol Bioeng. 2017;114:2043–2056. doi:10.1002/bit.26329.
   PubMed Web of Science ®Google Scholar
• Dostalek M, Prueksaritanont T, Kelley RF. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. MAbs. 2017;9:756–766. doi:10.1080/19420862.2017.1323160.
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10:345–352. doi:10.1038/nri2747.
   PubMed Web of Science ®Google Scholar
• Nowak C, Cheung K, Dellatore J,M, Katiyar A, Bhat R, Sun J, Ponniah G, Neill A, Mason B, Beck A, et al. Forced degradation of recombinant monoclonal antibodies: A practical guide. MAbs. 2017;9:1217–1230. doi:10.1080/19420862.2017.1368602.
   PubMed Web of Science ®Google Scholar
• Bults P, Bischoff R, Bakker H, Gietema JA, van de Merbel NC. LC-MS/MS-based monitoring of in vivo protein biotransformation: quantitative determination of trastuzumab and its deamidation products in human plasma. Anal Chem. 2016;88:1871–1877. doi:10.1021/acs.analchem.5b04276.
   PubMed Web of Science ®Google Scholar
• Huang L, Lu J, Wroblewski VJ, Beals JM, Riggin RM. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem. 2005;77:1432–1439. doi:10.1021/ac0494174.
   PubMed Web of Science ®Google Scholar
• Phillips JJ, Buchanan A, Andrews J, Chodorge M, Sridharan S, Mitchell L, Burmeister N, Kippen AD, Vaughan TJ, Higazi DR, et al. Rate of asparagine deamidation in a monoclonal antibody correlating with hydrogen exchange rate at adjacent downstream residues. Anal Chem. 2017;89:2361–2368. doi:10.1021/acs.analchem.6b04158.
   PubMed Web of Science ®Google Scholar
• Tran JC, Tran D, Hilderbrand A, Andersen N, Huang T, Reif K, Hotzel I, Stefanich EG, Liu Y, Wang J. Automated affinity capture and on-tip digestion to accurately quantitate in vivo deamidation of therapeutic antibodies. Anal Chem. 2016;88:11521–11526. doi:10.1021/acs.analchem.6b02766.
   PubMed Web of Science ®Google Scholar
• Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, Kirchmeier M, Corvaïa N, Ionescu R, Beck A. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem. 2009;392:145–154. doi:10.1016/j.ab.2009.05.043.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl. 2001;752:233–245.
   PubMed Web of Science ®Google Scholar
• Chelius D, Rehder DS, Bondarenko PV. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal Chem. 2005;77:6004–6011. doi:10.1021/ac050672d.
   PubMed Web of Science ®Google Scholar
• Sinha S, Zhang L, Duan S, Williams TD, Vlasak J, Ionescu R, Topp EM. Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Sci. 2009;18:1573–1584. doi:10.1002/pro.173.
   PubMed Web of Science ®Google Scholar
• Liu YD, van Enk JZ, Flynn GC. Human antibody Fc deamidation in vivo. Biologicals. 2009;37:313–322. doi:10.1016/j.biologicals.2009.06.001.
   PubMed Web of Science ®Google Scholar
• Cacia J, Keck R, Presta LG, Frenz J. Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. Biochemistry. 1996;35:1897–1903. doi:10.1021/bi951526c.
   PubMed Web of Science ®Google Scholar
• Rehder DS, Chelius D, McAuley A, Dillon TM, Xiao G, Crouse-Zeineddini J, Vardanyan L, Perico N, Mukku V, Brems DN, et al. Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. Biochemistry. 2008;47:2518–2530. doi:10.1021/bi7018223.
   PubMed Web of Science ®Google Scholar
• Sreedhara A, Cordoba A, Zhu Q, Kwong J, Liu J. Characterization of the isomerization products of aspartate residues at two different sites in a monoclonal antibody. Pharm Res. 2012;29:187–197. doi:10.1007/s11095-011-0534-2.
   PubMed Web of Science ®Google Scholar
• Wakankar AA, Borchardt RT, Eigenbrot C, Shia S, Wang YJ, Shire SJ, Liu JL. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry. 2007;46:1534–1544. doi:10.1021/bi061500t.
   PubMed Web of Science ®Google Scholar
• Wakankar AA, Liu J, Vandervelde D, Wang YJ, Shire SJ, Borchardt RT. The effect of cosolutes on the isomerization of aspartic acid residues and conformational stability in a monoclonal antibody. J Pharm Sci. 2007;96:1708–1718. doi:10.1002/jps.20823.
   PubMed Web of Science ®Google Scholar
• Yan Y, Wei H, Fu Y, Jusuf S, Zeng M, Ludwig R, Krystek SR, Chen G, Tao L, Das TK. Isomerization and oxidation in the complementarity-determining regions of a monoclonal antibody: A study of the modification-structure-function correlations by hydrogen-deuterium exchange mass spectrometry. Anal Chem. 2016;88:2041–2050. doi:10.1021/acs.analchem.5b02800.
   PubMed Web of Science ®Google Scholar
• Chu GC, Chelius D, Xiao G, Khor HK, Coulibaly S, Bondarenko PV. Accumulation of succinimide in a recombinant monoclonal antibody in mildly acidic buffers under elevated temperatures. Pharm Res. 2007;24:1145–1156. doi:10.1007/s11095-007-9241-4.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Jones L, Shpektor D, Kodama P, Wallace A, Balland A, Bailey R, Zhang Y. Separation and characterization of an IgG2 antibody containing a cyclic imide in CDR1 of light chain by hydrophobic interaction chromatography and mass spectrometry. Anal Chem. 2008;80:3168–3174. doi:10.1021/ac702245c.
   PubMed Web of Science ®Google Scholar
• Yan B, Steen S, Hambly D, Valliere-Douglass J, Vanden Bos T, Smallwood S, Yates Z, Arroll T, Han Y, Gadgil H, et al. Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. J Pharm Sci. 2009;98:3509–3521. doi:10.1002/jps.21655.
   PubMed Web of Science ®Google Scholar
• Mo J, Yan Q, So CK, Soden T, Lewis MJ, Hu P. Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen/deuterium exchange mass spectrometry. Anal Chem. 2016;88:9495–9502. doi:10.1021/acs.analchem.6b01958.
   PubMed Web of Science ®Google Scholar
• Liu D, Ren D, Huang H, Dankberg J, Rosenfeld R, Cocco MJ, Li L, Brems DN, Remmele RL. Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. Biochemistry. 2008;47:5088–5100. doi:10.1021/bi702238b.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Xiang T, Chumsae C. Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. Mol Immunol. 2008;45:701–708. doi:10.1016/j.molimm.2007.07.012.
   PubMed Web of Science ®Google Scholar
• Zhang A, Hu P, MacGregor P, Xue Y, Fan H, Suchecki P, Olszewski L, Liu A. Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variation using hydrogen/deuterium exchange mass spectrometry and structural modeling. Anal Chem. 2014;86:3468–3475. doi:10.1021/ac404130a.
   PubMed Web of Science ®Google Scholar
• Bertolotti-Ciarlet A, Wang W, Lownes R, Pristatsky P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksaritanont T, et al. Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. Mol Immunol. 2009;46:1878–1882. doi:10.1016/j.molimm.2009.02.002.
   PubMed Web of Science ®Google Scholar
• Pan H, Chen K, Chu L, Kinderman F, Apostol I, Huang G. Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Sci. 2009;18:424–433. doi:10.1002/pro.45.
   PubMed Web of Science ®Google Scholar
• Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol. 2011;48:860–866. doi:10.1016/j.molimm.2010.12.009.
   PubMed Web of Science ®Google Scholar
• Dashivets T, Stracke J, Dengl S, Knaupp A, Pollmann J, Buchner J, Schlothauer T. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies. MAbs. 2016;8:1525–1535. doi:10.1080/19420862.2016.1231277.
   PubMed Web of Science ®Google Scholar
• Qi P, Volkin DB, Zhao H, Nedved ML, Hughes R, Bass R, Yi SC, Panek ME, Wang D, Dalmonte P, et al. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. J Pharm Sci. 2009;98:3117–3130. doi:10.1002/jps.21617.
   PubMed Web of Science ®Google Scholar
• Wei Z, Feng J, Lin H-Y, Mullapudi S, Bishop E, Tous GI, Casas-Finet J, Hakki F, Strouse R, Schenerman MA. Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. Anal Chem. 2007;79:2797–2805. doi:10.1021/ac062311j.
   PubMed Web of Science ®Google Scholar
• Li Y, Polozova A, Gruia F, Feng J. Characterization of the degradation products of a color-changed monoclonal antibody: tryptophan-derived chromophores. Anal Chem. 2014;86:6850–6857. doi:10.1021/ac404218t.
   PubMed Web of Science ®Google Scholar
• Banks DD, Gadgil HS, Pipes GD, Bondarenko PV, Hobbs V, Scavezze JL, Kim J, Jiang X-R, Mukku V, Dillon TM. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J Pharm Sci. 2008;97:775–790. doi:10.1002/jps.21014.
   PubMed Web of Science ®Google Scholar
• Gadgil HS, Bondarenko PV, Pipes GD, Dillon TM, Banks D, Abel J, Kleemann GR, Treuheit MJ. Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis. Anal Biochem. 2006;355:165–174. doi:10.1016/j.ab.2006.05.037.
   PubMed Web of Science ®Google Scholar
• Almagro JC, Raghunathan G, Beil E, Janecki DJ, Chen Q, Dinh T, LaCombe A, Connor J, Ware M, Kim PH, et al. Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chain. J Mol Recognit. 2012;25:125–135. doi:10.1002/jmr.1168.
   PubMed Web of Science ®Google Scholar
• Leung SO, Dion AS, Pellegrini MC, Losman MJ, Grebenau RC, Goldenberg DM, Hansen HJ. Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site. Int J Cancer. 1995;60:534–538.
   PubMed Web of Science ®Google Scholar
• Co MS, Scheinberg DA, Avdalovic NM, McGraw K, Vasquez M, Caron PC, Queen C. Genetically engineered deglycosylation of the variable domain increases the affinity of an anti-CD33 monoclonal antibody. Mol Immunol. 1993;30:1361–1367.
   PubMed Web of Science ®Google Scholar
• Wright A, Tao MH, Kabat EA, Morrison SL. Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure. Embo J. 1991;10:2717–2723.
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Trinh RK, Martinez AR, Morrison SL. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1–>6) dextran antibody. J Immunol. 1999;162:2162–2170.
   PubMed Web of Science ®Google Scholar
• Leibiger H, Wustner D, Stigler RD, Marx U. Variable domain-linked oligosaccharides of a human monoclonal IgG: structure and influence on antigen binding. Biochem J. 1999;338(Pt 2):529–538.
   PubMed Web of Science ®Google Scholar
• Wallick SC, Kabat EA, Morrison SL. Glycosylation of a VH residue of a monoclonal antibody against alpha (1—-6) dextran increases its affinity for antigen. J Exp Med. 1988;168:1099–1109.
   PubMed Web of Science ®Google Scholar
• Huang L, Biolsi S, Bales KR, Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem. 2006;349:197–207. doi:10.1016/j.ab.2005.11.012.
   PubMed Web of Science ®Google Scholar
• Lammerts van Bueren JJ, Rispens T, Verploegen S, van der Palen-Merkus T, Stapel S, Workman LJ, James H, van Berkel PHC, van de Winkel JGJ, Platts-Mills TAE, et al. Anti-galactose-alpha-1,3-galactose IgE from allergic patients does not bind alpha-galactosylated glycans on intact therapeutic antibody Fc domains. Nat Biotechnol. 2011;29:574–576. doi:10.1038/nbt.1912.
   PubMed Web of Science ®Google Scholar
• Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology. 2000;10:477–486.
   PubMed Web of Science ®Google Scholar
• Seeliger D, Schulz P, Litzenburger T, Spitz J, Hoerer S, Blech M, Enenkel B, Studts JM, Garidel P, Karow AR. Boosting antibody developability through rational sequence optimization. MAbs. 2015;7:505–515. doi:10.1080/19420862.2015.1017695.
   PubMed Web of Science ®Google Scholar
• Dick LW Jr., Kim C, Qiu D, Cheng KC. Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol Bioeng. 2007;97:544–553. doi:10.1002/bit.21260.
   PubMed Web of Science ®Google Scholar
• Lyubarskaya Y, Houde D, Woodard J, Murphy D, Mhatre R. Analysis of recombinant monoclonal antibody isoforms by electrospray ionization mass spectrometry as a strategy for streamlining characterization of recombinant monoclonal antibody charge heterogeneity. Anal Biochem. 2006;348:24–39. doi:10.1016/j.ab.2005.10.003.
   PubMed Web of Science ®Google Scholar
• Liu YD, Goetze AM, Bass RB, Flynn GC. N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. J Biol Chem. 2011;286:11211–11217. doi:10.1074/jbc.M110.185041.
   PubMed Web of Science ®Google Scholar
• Antes B, Amon S, Rizzi A, Wiederkum S, Kainer M, Szolar O, Fido M, Kircheis R, Nechansky A. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:250–256. doi:10.1016/j.jchromb.2007.01.024.
   PubMed Web of Science ®Google Scholar
• Jiang G, Yu C, Yadav DB, Hu Z, Amurao A, Duenas E, Wong M, Iverson M, Zheng K, Lam X, et al. Evaluation of Heavy-Chain C-Terminal Deletion on Product Quality and Pharmacokinetics of Monoclonal Antibodies. J Pharm Sci. 2016;105:2066–2072. doi:10.1016/j.xphs.2016.04.027.
   PubMed Web of Science ®Google Scholar
• van Den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, et al. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation. MAbs. 2015;7:672–680. doi:10.1080/19420862.2015.1046665.
   PubMed Web of Science ®Google Scholar
• Cai B, Pan H, Flynn GC. C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo. Biotechnol Bioeng. 2011;108:404–412. doi:10.1002/bit.22933.
   PubMed Web of Science ®Google Scholar
• Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2:256–265.
   PubMed Web of Science ®Google Scholar
• West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease. Aliment Pharmacol Ther. 2008;28:1122–1126. doi:10.1111/j.1365-2036.2008.03828.x.
   PubMed Web of Science ®Google Scholar
• Ducancel F, Muller BH. Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs. 2012;4:445–457. doi:10.4161/mabs.20776.
   PubMed Web of Science ®Google Scholar
• Seeliger D. Development of scoring functions for antibody sequence assessment and optimization. PLoS One. 2013;8:e76909. doi:10.1371/journal.pone.0076909.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8:E501–7. doi:10.1208/aapsj080359.
   PubMed Web of Science ®Google Scholar
• Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm Sci. 2011;100:5081–5095. doi:10.1002/jps.22705.
   PubMed Web of Science ®Google Scholar
• Buck PM, Kumar S, Wang X, Agrawal NJ, Trout BL, Singh SK. Computational methods to predict therapeutic protein aggregation. Methods Mol Biol. 2012;899:425–451. doi:10.1007/978-1-61779-921-1_26.
   PubMedGoogle Scholar
• Courtois F, Schneider CP, Agrawal NJ, Trout BL. Rational design of biobetters with enhanced stability. J Pharm Sci. 2015;104:2433–2440. doi:10.1002/jps.24520.
   PubMed Web of Science ®Google Scholar
• Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL. Predictive tools for stabilization of therapeutic proteins. MAbs. 2009;1:580–582.
   PubMed Web of Science ®Google Scholar
• Wang X, Singh SK, Kumar S. Potential aggregation-prone regions in complementarity-determining regions of antibodies and their contribution towards antigen recognition: a computational analysis. Pharm Res. 2010;27:1512–1529. doi:10.1007/s11095-010-0143-5.
   PubMed Web of Science ®Google Scholar
• Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci U S A. 2012;109:10879–10884. doi:10.1073/pnas.1202866109.
   PubMed Web of Science ®Google Scholar
• Courtois F, Agrawal NJ, Lauer TM, Trout BL. Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs. 2016;8:99–112. doi:10.1080/19420862.2015.1112477.
   PubMed Web of Science ®Google Scholar
• Abiri N, Pang J, Ou J, Shi B, Wang X, Zhang S, Sun Y, Yang D, Wang Z. Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA. PLoS One. 2018;13:e0193339. doi:10.1371/journal.pone.0193339.
   PubMed Web of Science ®Google Scholar
• Jawa V, Joubert MK, Zhang Q, Deshpande M, Hapuarachchi S, Hall MP, Flynn GC. Evaluating immunogenicity risk due to host cell protein impurities in antibody-based biotherapeutics. AAPS J. 2016;18:1439–1452. doi:10.1208/s12248-016-9948-4.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Luo J, O’Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, et al. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel. 2010;23:643–651. doi:10.1093/protein/gzq037.
   PubMed Web of Science ®Google Scholar
• Nichols P, Li L, Kumar S, Buck PM, Singh SK, Goswami S, Balthazor B, Conley TR, Sek D, Allen MJ. Rational design of viscosity reducing mutants of a monoclonal antibody: hydrophobic versus electrostatic inter-molecular interactions. MAbs. 2015;7:212–230. doi:10.4161/19420862.2014.985504.
   PubMed Web of Science ®Google Scholar
• Pindrus M, Shire SJ, Kelley RF, Demeule B, Wong R, Xu Y, Yadav S. Solubility challenges in high concentration monoclonal antibody formulations: relationship with amino acid sequence and intermolecular interactions. Mol Pharm. 2015;12:3896–3907. doi:10.1021/acs.molpharmaceut.5b00336.
   PubMed Web of Science ®Google Scholar
• Yadav S, Sreedhara A, Kanai S, Liu J, Lien S, Lowman H, Kalonia DS, Shire SJ. Establishing a link between amino acid sequences and self-associating and viscoelastic behavior of two closely related monoclonal antibodies. Pharm Res. 2011;28:1750–1764. doi:10.1007/s11095-011-0410-0.
   PubMed Web of Science ®Google Scholar
• Yadav S, Laue TM, Kalonia DS, Singh SN, Shire SJ. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions. Mol Pharm. 2012;9:791–802. doi:10.1021/mp200566k.
   PubMed Web of Science ®Google Scholar
• Werner RG, Kopp K, Schlueter M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr. 2007;96:17–22. doi:10.1111/j.1651-2227.2007.00199.x.
   PubMed Web of Science ®Google Scholar
• Tiller KE, Tessier PM. Advances in antibody design. Annu Rev Biomed Eng. 2015;17:191–216. doi:10.1146/annurev-bioeng-071114-040733.
   PubMed Web of Science ®Google Scholar
• Kuhn AB, Kube S, Karow-Zwick AR, Seeliger D, Garidel P, Blech M, Schäfer LV. Improved solution-state properties of monoclonal antibodies by targeted mutations. J Phys Chem B. 2017;121:10818–10827. doi:10.1021/acs.jpcb.7b09126.
   PubMed Web of Science ®Google Scholar
• Casaz P, Boucher E, Wollacott R, Pierce BG, Rivera R, Sedic M, Ozturk S, Thomas WD, Wang Y. Resolving self-association of a therapeutic antibody by formulation optimization and molecular approaches. MAbs. 2014;6:1533–1539. doi:10.4161/19420862.2014.975658.
   PubMed Web of Science ®Google Scholar
• Liu L. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins. Protein Cell. 2018;9:15–32. doi:10.1007/s13238-017-0408-4.
   PubMed Web of Science ®Google Scholar
• C S, Günther R, Rhiel L, Becker S, Toleikis L, Doerner A, Becker J, Schönemann A, Nasu D, Neuteboom B, et al. A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display. MAbs. 2015;7:13.
   Web of Science ®Google Scholar
• Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs. 2015;7:483–493. doi:10.1080/19420862.2015.1016696.
   PubMed Web of Science ®Google Scholar
• Ayoub D, Jabs W, Resemann A, Evers W, Evans C, Main L, Baessmann C, Wagner-Rousset E, Suckau D, Beck A. Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques. MAbs. 2013;5:699–710. doi:10.4161/mabs.25423.
   PubMed Web of Science ®Google Scholar
• Guo D, Gao A, Michels DA, Feeney L, Eng M, Chan B, Laird MW, Zhang B, Yu XC, Joly J, et al. Mechanisms of unintended amino acid sequence changes in recombinant monoclonal antibodies expressed in Chinese Hamster Ovary (CHO) cells. Biotechnol Bioeng. 2010;107:163–171. doi:10.1002/bit.22780.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Murnane AA, Utter SL, Wagner KL, Cox ET, Polastri GD, Helder JC, Sliwkowski MB. Assessing genetic heterogeneity in production cell lines: detection by peptide mapping of a low level Tyr to Gln sequence variant in a recombinant antibody. Biotechnology (N Y). 1993;11:1293–1297.
   PubMedGoogle Scholar
• Khetan A, Huang Y-M, Dolnikova J, Pederson NE, Wen D, Yusuf-Makagiansar H, Chen P, Ryll T. Control of misincorporation of serine for asparagine during antibody production using CHO cells. Biotechnol Bioeng. 2010;107:116–123. doi:10.1002/bit.22771.
   PubMed Web of Science ®Google Scholar
• Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang Y-M, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem. 2009;284:32686–32694. doi:10.1074/jbc.M109.059360.
   PubMed Web of Science ®Google Scholar
• Yu XC, Borisov OV, Alvarez M, Michels DA, Wang YJ, Ling V. Identification of codon-specific serine to asparagine mistranslation in recombinant monoclonal antibodies by high-resolution mass spectrometry. Anal Chem. 2009;81:9282–9290. doi:10.1021/ac901541h.
   PubMed Web of Science ®Google Scholar
• Que HZ, Yang Y, Zhang J, Derfus G, Amanullah A. Sequence variant analysis using peptide mapping by LC–MS/MS. Bioprocess Int. 2010;8:52–60.
   Google Scholar
• Yang Y, Strahan A, Li C, Shen A, Liu H, Ouyang J, Katta V, Francissen K, Zhang B. Detecting low level sequence variants in recombinant monoclonal antibodies. MAbs. 2010;2:285–298.
   PubMed Web of Science ®Google Scholar
• Zeck A, Regula JT, Larraillet V, Mautz B, Popp O, Göpfert U, Wiegeshoff F, Vollertsen UEE, Gorr IH, Koll H, et al. Low level sequence variant analysis of recombinant proteins: an optimized approach. PLoS One. 2012;7:e40328. doi:10.1371/journal.pone.0040328.
   PubMed Web of Science ®Google Scholar
• Neill A, Nowak C, Patel R, Ponniah G, Gonzalez N, Miano D, Liu H. Characterization of recombinant monoclonal antibody charge variants using OFFGEL fractionation, weak anion exchange chromatography, and mass spectrometry. Anal Chem. 2015;87:6204–6211. doi:10.1021/acs.analchem.5b01452.
   PubMed Web of Science ®Google Scholar
• Sinha S, Pipes G, Topp EM, Bondarenko PV, Treuheit MJ, Gadgil HS. Comparison of LC and LC/MS methods for quantifying N-glycosylation in recombinant IgGs. J Am Soc Mass Spectrom. 2008;19:1643–1654. doi:10.1016/j.jasms.2008.07.004.
   PubMed Web of Science ®Google Scholar
• Kleemann GR, Beierle J, Nichols AC, Dillon TM, Pipes GD, Bondarenko PV. Characterization of IgG1 immunoglobulins and peptide-Fc fusion proteins by limited proteolysis in conjunction with LC-MS. Anal Chem. 2008;80:2001–2009. doi:10.1021/ac701629v.
   PubMed Web of Science ®Google Scholar
• An Y, Zhang Y, Mueller HM, Shameem M, Chen X. A new tool for monoclonal antibody analysis: application of IdeS proteolysis in IgG domain-specific characterization. MAbs. 2014;6:879–893. doi:10.4161/mabs.28762.
   PubMed Web of Science ®Google Scholar
• Fornelli L, Ayoub D, Aizikov K, Beck A, Tsybin YO. Middle-down analysis of monoclonal antibodies with electron transfer dissociation orbitrap fourier transform mass spectrometry. Anal Chem. 2014;86:3005–3012. doi:10.1021/ac4036857.
   PubMed Web of Science ®Google Scholar
• Amano M, Hasegawa J, Kobayashi N, Kishi N, Nakazawa T, Uchiyama S, Fukui K. Specific racemization of heavy-chain cysteine-220 in the hinge region of immunoglobulin gamma 1 as a possible cause of degradation during storage. Anal Chem. 2011;83:3857–3864. doi:10.1021/ac200321v.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Flynn GC. Cysteine racemization on IgG heavy and light chains. J Biol Chem. 2013;288:34325–34335. doi:10.1074/jbc.M113.506915.
   PubMed Web of Science ®Google Scholar
• Huang L, Lu X, Gough PC, De Felippis MR. Identification of racemization sites using deuterium labeling and tandem mass spectrometry. Anal Chem. 2010;82:6363–6369. doi:10.1021/ac101348w.
   PubMed Web of Science ®Google Scholar
• Kaschak T, Boyd D, Lu F, Derfus G, Kluck B, Nogal B, Emery C, Summers C, Zheng K, Bayer R, et al. Characterization of the basic charge variants of a human IgG1: effect of copper concentration in cell culture media. MAbs. 2011;3:577–583. doi:10.4161/mabs.3.6.17959.
   PubMed Web of Science ®Google Scholar
• Kotia RB, Raghani AR. Analysis of monoclonal antibody product heterogeneity resulting from alternate cleavage sites of signal peptide. Anal Biochem. 2010;399:190–195. doi:10.1016/j.ab.2010.01.008.
   PubMed Web of Science ®Google Scholar
• Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, et al. Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs. 2010;2:613–624. doi:10.4161/mabs.2.6.13333.
   PubMed Web of Science ®Google Scholar
• Meert CD, Brady LJ, Guo A, Balland A. Characterization of antibody charge heterogeneity resolved by preparative immobilized pH gradients. Anal Chem. 2010;82:3510–3518. doi:10.1021/ac902408r.
   PubMed Web of Science ®Google Scholar
• Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall’Acqua W, Minter R, et al. Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs. 2013;5:255–262. doi:10.4161/mabs.23392.
   PubMed Web of Science ®Google Scholar
• Chumsae C, Zhou LL, Shen Y, Wohlgemuth J, Fung E, Burton R, Radziejewski C, Zhou ZS. Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody. Anal Chem. 2014;86:8932–8936. doi:10.1021/ac502179m.
   PubMed Web of Science ®Google Scholar
• Quan C, Alcala E, Petkovska I, Matthews D, Canova-Davis E, Taticek R, Ma S. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal Biochem. 2008;373:179–191. doi:10.1016/j.ab.2007.09.027.
   PubMed Web of Science ®Google Scholar
• Zhang B, Yang Y, Yuk I, Pai R, McKay P, Eigenbrot C, Dennis M, Katta V, Francissen KC. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal Chem. 2008;80:2379–2390. doi:10.1021/ac701810q.
   PubMed Web of Science ®Google Scholar
• Banks DD, Hambly DM, Scavezze JL, Siska CC, Stackhouse NL, Gadgil HS. The effect of sucrose hydrolysis on the stability of protein therapeutics during accelerated formulation studies. J Pharm Sci. 2009;98:4501–4510. doi:10.1002/jps.21749.
   PubMed Web of Science ®Google Scholar
• Fischer S, Hoernschemeyer J, Mahler HC. Glycation during storage and administration of monoclonal antibody formulations. Eur J Pharm Biopharm. 2008;70:42–50. doi:10.1016/j.ejpb.2008.04.021.
   PubMed Web of Science ®Google Scholar
• Gadgil HS, Bondarenko PV, Pipes G, Rehder D, McAuley A, Perico N, Dillon T, Ricci M, Treuheit M. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J Pharm Sci. 2007;96:2607–2621. doi:10.1002/jps.20966.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Arroll T, Chu L, Flynn GC. Rates and impact of human antibody glycation in vivo. Glycobiology. 2012;22:221–234. doi:10.1093/glycob/cwr141.
   PubMed Web of Science ®Google Scholar
• Miller AK, Hambly DM, Kerwin BA, Treuheit MJ, Gadgil HS. Characterization of site-specific glycation during process development of a human therapeutic monoclonal antibody. J Pharm Sci. 2011;100:2543–2550. doi:10.1002/jps.22504.
   PubMed Web of Science ®Google Scholar
• Mo J, Jin R, Yan Q, Sokolowska I, Lewis MJ, Hu P. Quantitative analysis of glycation and its impact on antigen binding. MAbs. 2018;10:406–415. doi:10.1080/19420862.2018.1438796.
   PubMed Web of Science ®Google Scholar
• Butko M, Pallat H, Cordoba A, Yu XC. Recombinant antibody color resulting from advanced glycation end product modifications. Anal Chem. 2014;86:9816–9823. doi:10.1021/ac5024099.
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol. 2008;20:471–478. doi:10.1016/j.coi.2008.06.007.
   PubMed Web of Science ®Google Scholar
• Chumsae C, Hossler P, Raharimampionona H, Zhou Y, McDermott S, Racicot C, Radziejewski C, Zhou ZS. When good intentions go awry: modification of a recombinant monoclonal antibody in chemically defined cell culture by xylosone, an oxidative product of ascorbic acid. Anal Chem. 2015;87:7529–7534. doi:10.1021/acs.analchem.5b00801.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–26740. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466–3473. doi:10.1074/jbc.M210665200.
   PubMed Web of Science ®Google Scholar
• Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010;70:4481–4489. doi:10.1158/0008-5472.CAN-09-3704.
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87:614–622. doi:10.1002/bit.20151.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass JF, Brady LJ, Farnsworth C, Pace D, Balland A, Wallace A, Wang W, Treuheit MJ, Yan B. O-fucosylation of an antibody light chain: characterization of a modification occurring on an IgG1 molecule. Glycobiology. 2009;19:144–152. doi:10.1093/glycob/cwn116.
   PubMed Web of Science ®Google Scholar
• Santora LC, Stanley K, Krull IS, Grant K. Characterization of maleuric acid derivatives on transgenic human monoclonal antibody due to post-secretional modifications in goat milk. Biomed Chromatogr. 2006;20:843–856. doi:10.1002/bmc.603.
   PubMed Web of Science ®Google Scholar
• Dick LW Jr., Qiu D, Mahon D, Adamo M, Cheng KC. C-terminal lysine variants in fully human monoclonal antibodies: investigation of test methods and possible causes. Biotechnol Bioeng. 2008;100:1132–1143. doi:10.1002/bit.21855.
   PubMed Web of Science ®Google Scholar
• Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A. 1995;705:129–134.
   PubMed Web of Science ®Google Scholar
• Kita A, Ponniah G, Nowak C, Liu H. Characterization of cysteinylation and trisulfide bonds in a recombinant monoclonal antibody. Anal Chem. 2016;88:5430–5437. doi:10.1021/acs.analchem.6b00822.
   PubMed Web of Science ®Google Scholar
• McSherry T, McSherry J, Ozaeta P, Longenecker K, Ramsay C, Fishpaugh J, Allen S. Cysteinylation of a monoclonal antibody leads to its inactivation. MAbs. 2016;8:718–725. doi:10.1080/19420862.2016.1160179.
   PubMed Web of Science ®Google Scholar
• Zhao J, Saunders J, Schussler SD, Rios S, Insaidoo FK, Fridman AL, Li H, Liu Y-H. Characterization of a novel modification of a CHO-produced mAb: evidence for the presence of tyrosine sulfation. MAbs. 2017;9:985–995. doi:10.1080/19420862.2017.1332552.
   PubMed Web of Science ®Google Scholar
• Chumsae C, Gifford K, Lian W, Liu H, Radziejewski CH, Zhou ZS. Arginine modifications by methylglyoxal: discovery in a recombinant monoclonal antibody and contribution to acidic species. Anal Chem. 2013;85:11401–11409. doi:10.1021/ac402384y.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass JF, Connell-Crowley L, Jensen R, Schnier PD, Trilisky E, Leith M, Follstad BD, Kerr J, Lewis N, Vunnum S, et al. Photochemical degradation of citrate buffers leads to covalent acetonation of recombinant protein therapeutics. Protein Sci. 2010;19:2152–2163. doi:10.1002/pro.495.
   PubMed Web of Science ®Google Scholar
• Gu S, Wen D, Weinreb PH, Sun Y, Zhang L, Foley SF, Kshirsagar R, Evans D, Mi S, Meier W, et al. Characterization of trisulfide modification in antibodies. Anal Biochem. 2010;400:89–98. doi:10.1016/j.ab.2010.01.019.
   PubMed Web of Science ®Google Scholar
• Pristatsky P, Cohen SL, Krantz D, Acevedo J, Ionescu R, Vlasak J. Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody. Anal Chem. 2009;81:6148–6155. doi:10.1021/ac9006254.
   PubMed Web of Science ®Google Scholar
• Lam XM, Yang JY, Cleland JL. Antioxidants for prevention of methionine oxidation in recombinant monoclonal antibody HER2. J Pharm Sci. 1997;86:1250–1255. doi:10.1021/js970143s.
   PubMed Web of Science ®Google Scholar
• Xie Q, Moore B, Beardsley RL. Discovery and characterization of hydroxylysine in recombinant monoclonal antibodies. MAbs. 2016;8:371–378. doi:10.1080/19420862.2015.1122148.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang S, Liu J, Raghani A. Determination of tryptophan oxidation of monoclonal antibody by reversed phase high performance liquid chromatography. J Chromatogr A. 2007;1156:174–182. doi:10.1016/j.chroma.2007.01.140.
   PubMed Web of Science ®Google Scholar
• Yang Y, Stella C, Wang W, Schoneich C, Gennaro L. Characterization of oxidative carbonylation on recombinant monoclonal antibodies. Anal Chem. 2014;86:4799–4806. doi:10.1021/ac4039866.
   PubMed Web of Science ®Google Scholar
• Liu M, Zhang Z, Cheetham J, Ren D, Zhou ZS. Discovery and characterization of a photo-oxidative histidine-histidine cross-link in IgG1 antibody utilizing (1)(8)O-labeling and mass spectrometry. Anal Chem. 2014;86:4940–4948. doi:10.1021/ac500334k.
   PubMed Web of Science ®Google Scholar
• Harris RJ. Heterogeneity of recombinant antibodies: linking structure to function. Dev Biol (Basel). 2005;122:117–127.
   PubMedGoogle Scholar
• Ouellette D, Alessandri L, Chin A, Grinnell C, Tarcsa E, Radziejewski C, Correia I. Studies in serum support rapid formation of disulfide bond between unpaired cysteine residues in the VH domain of an immunoglobulin G1 molecule. Anal Biochem. 2010;397:37–47. doi:10.1016/j.ab.2009.09.027.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang J, Hewitt D, Tran B, Gao X, Qiu ZJ, Tejada M, Gazzano-Santoro H, Kao Y-H. Identification and characterization of buried unpaired cysteines in a recombinant monoclonal IgG1 antibody. Anal Chem. 2012;84:7112–7123. doi:10.1021/ac301426h.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Sun J. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;837:35–43. doi:10.1016/j.jchromb.2006.03.053.
   PubMed Web of Science ®Google Scholar
• Wang L, Amphlett G, Lambert JM, Blättler W, Zhang W. Structural characterization of a recombinant monoclonal antibody by electrospray time-of-flight mass spectrometry. Pharm Res. 2005;22:1338–1349. doi:10.1007/s11095-005-5267-7.
   PubMed Web of Science ®Google Scholar
• Moorhouse KG, Nashabeh W, Deveney J, Bjork NS, Mulkerrin MG, Ryskamp T. Validation of an HPLC method for the analysis of the charge heterogeneity of the recombinant monoclonal antibody IDEC-C2B8 after papain digestion. J Pharm Biomed Anal. 1997;16:593–603.
   PubMed Web of Science ®Google Scholar
• Ouellette D, Chumsae C, Clabbers A, Radziejewski C, Correia I. Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule. MAbs. 2013;5:432–444. doi:10.4161/mabs.24458.
   PubMed Web of Science ®Google Scholar
• Yu L, Vizel A, Huff MB, Young M, Remmele RL Jr., He B. Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development. J Pharm Biomed Anal. 2006;42:455–463. doi:10.1016/j.jpba.2006.05.008.
   PubMed Web of Science ®Google Scholar
• Chelius D, Jing K, Lueras A, Rehder DS, Dillon TM, Vizel A, Rajan RS, Li T, Treuheit MJ, Bondarenko PV. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem. 2006;78:2370–2376. doi:10.1021/ac051827k.
   PubMed Web of Science ®Google Scholar
• Huang HZ, Nichols A, Liu D. Direct identification and quantification of aspartyl succinimide in an IgG2 mAb by RapiGest assisted digestion. Anal Chem. 2009;81:1686–1692. doi:10.1021/ac802708s.
   PubMed Web of Science ®Google Scholar
• Yu XC, Joe K, Zhang Y, Adriano A, Wang Y, Gazzano-Santoro H, Keck RG, Deperalta G, Ling V. Accurate determination of succinimide degradation products using high fidelity trypsin digestion peptide map analysis. Anal Chem. 2011;83:5912–5919. doi:10.1021/ac200750u.
   PubMed Web of Science ®Google Scholar
• Valliere-Douglass J, Wallace A, Balland A. Separation of populations of antibody variants by fine tuning of hydrophobic-interaction chromatography operating conditions. J Chromatogr A. 2008;1214:81–89. doi:10.1016/j.chroma.2008.10.078.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Schenauer MR, McCarter JD, Flynn GC. IgG1 thioether bond formation in vivo. J Biol Chem. 2013;288:16371–16382. doi:10.1074/jbc.M113.468397.
   PubMed Web of Science ®Google Scholar
• Tous GI, Wei Z, Feng J, Bilbulian S, Bowen S, Smith J, Strouse R, McGeehan P, Casas-Finet J, Schenerman MA. Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains. Anal Chem. 2005;77:2675–2682. doi:10.1021/ac0500582.
   PubMed Web of Science ®Google Scholar
• Johnson KA, Paisley-Flango K, Tangarone BS, Porter TJ, Rouse JC. Cation exchange-HPLC and mass spectrometry reveal C-terminal amidation of an IgG1 heavy chain. Anal Biochem. 2007;360:75–83. doi:10.1016/j.ab.2006.10.012.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Terashima I, Kamata K, Koga A. C-terminal modification of monoclonal antibody drugs: amidated species as a general product-related substance. Int J Biol Macromol. 2013;52:139–147. doi:10.1016/j.ijbiomac.2012.09.016.
   PubMed Web of Science ®Google Scholar
• Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, Rademacher TW, Mizuochi T, Taniguchi T, Matsuta K. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316:452–457.
   PubMed Web of Science ®Google Scholar
• Flynn GC, Chen X, Liu YD, Shah B, Zhang Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol. 2010;47:2074–2082. doi:10.1016/j.molimm.2010.04.006.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Nishimura M, Nagano M, Yagi H, Sasakawa H, Uchida K, Shitara K, Kato K. Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochim Biophys Acta. 2006;1760:693–700. doi:10.1016/j.bbagen.2005.10.002.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Church S, Ghirlando R, Ashton PR, Dong S, Goodall M, Lund J, Jefferis R. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol. 2000;37:697–706.
   PubMed Web of Science ®Google Scholar
• Mimura Y, Sondermann P, Ghirlando R, Lund J, Young SP, Goodall M, Jefferis R. Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem. 2001;276:45539–45547. doi:10.1074/jbc.M107478200.
   PubMed Web of Science ®Google Scholar
• Fang J, Richardson J, Du Z, Zhang Z. Effect of Fc-Glycan structure on the conformational stability of IgG revealed by hydrogen/deuterium exchange and limited proteolysis. Biochemistry. 2016;55:860–868. doi:10.1021/acs.biochem.5b01323.
   PubMed Web of Science ®Google Scholar
• Falck D, Jansen BC, Plomp R, Reusch D, Haberger M, Wuhrer M. Glycoforms of immunoglobulin G based biopharmaceuticals are differentially cleaved by trypsin due to the glycoform influence on higher-order structure. J Proteome Res. 2015;14:4019–4028. doi:10.1021/acs.jproteome.5b00573.
   PubMed Web of Science ®Google Scholar
• Lu Y, Westland K, Ma YH, Gadgil H. Evaluation of effects of Fc domain high-mannose glycan on antibody stability. J Pharm Sci. 2012;101:4107–4117. doi:10.1002/jps.23284.
   PubMed Web of Science ®Google Scholar
• Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. Increased serum clearance of oligomannose species present on a human IgG1 molecule. MAbs. 2012;4:509–520. doi:10.4161/mabs.20450.
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21:949–959. doi:10.1093/glycob/cwr027.
   PubMed Web of Science ®Google Scholar
• Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17:104–118. doi:10.1093/glycob/cwl057.
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med. 1994;180:1087–1096.
   PubMed Web of Science ®Google Scholar
• Wright A, Morrison SL. Effect of C2-associated carbohydrate structure on Ig effector function: studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol. 1998;160:3393–3402.
   PubMed Web of Science ®Google Scholar
• Yu M, Brown D, Reed C, Chung S, Lutman J, Stefanich E, Wong A, Stephan J-P, Bayer R. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs. 2012;4:475–487. doi:10.4161/mabs.20737.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, Culm-Merdek K, Park A, Pan C, Edmunds T. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng. 2008;99:652–665. doi:10.1002/bit.21598.
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10:101–111. doi:10.1038/nrd3365.
   PubMed Web of Science ®Google Scholar
• Ghirlando R, Lund J, Goodall M, Jefferis R. Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. Immunol Lett. 1999;68:47–52.
   PubMed Web of Science ®Google Scholar
• Houde D, Peng Y, Berkowitz SA, Engen JR. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics. 2010;9:1716–1728. doi:10.1074/mcp.M900540-MCP200.
   PubMed Web of Science ®Google Scholar
• Onitsuka M, Kawaguchi A, Asano R, Kumagai I, Honda K, Ohtake H, Omasa T. Glycosylation analysis of an aggregated antibody produced by Chinese hamster ovary cells in bioreactor culture. J Biosci Bioeng. 2014;117:639–644. doi:10.1016/j.jbiosc.2013.11.001.
   PubMed Web of Science ®Google Scholar
• Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals. 2008;36:41–47. doi:10.1016/j.biologicals.2007.05.003.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology. 2009;19:240–249. doi:10.1093/glycob/cwn120.
   PubMed Web of Science ®Google Scholar
• Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104:1866–1884. doi:10.1002/jps.24444.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Rueger P, Stracke JO, Hertenberger H, Fingas F, Kling L, Emrich T, Drabner G, Seeber S, Auer J, et al. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies. MAbs. 2013;5:576–586. doi:10.4161/mabs.24981.
   PubMed Web of Science ®Google Scholar
• Souders CA, Nelson SC, Wang Y, Crowley AR, Klempner MS, Thomas W Jr. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs. 2015;7:912–921. doi:10.1080/19420862.2015.1054585.
   PubMed Web of Science ®Google Scholar
• Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol J. 2011;6:38–44. doi:10.1002/biot.201000091.
   PubMed Web of Science ®Google Scholar
• He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci. 2010;99:1707–1720. doi:10.1002/jps.21955.
   PubMed Web of Science ®Google Scholar
• Nemergut M, Zoldak G, Schaefer JV, Kast F, Miskovsky P, Pluckthun A, Sedlak E. Analysis of IgG kinetic stability by differential scanning calorimetry, probe fluorescence and light scattering. Protein Sci. 2017;26:2229–2239. doi:10.1002/pro.3278.
   PubMed Web of Science ®Google Scholar
• Brader ML, Estey T, Bai S, Alston RW, Lucas KK, Lantz S, Landsman P, Maloney KM. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Mol Pharm. 2015;12:1005–1017. doi:10.1021/mp400666b.
   PubMed Web of Science ®Google Scholar
• Majumdar R, Esfandiary R, Bishop SM, Samra HS, Middaugh CR, Volkin DB, Weis DD. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. MAbs. 2015;7:84–95. doi:10.4161/19420862.2014.985494.
   PubMed Web of Science ®Google Scholar
• Shi S, Semple A, Cheung J, Shameem M. DSF method optimization and its application in predicting protein thermal aggregation kinetics. J Pharm Sci. 2013;102:2471–2483. doi:10.1002/jps.23633.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114:944–949. doi:10.1073/pnas.1616408114.
   PubMed Web of Science ®Google Scholar
• Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ. High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc. 2009;131:3794–3795. doi:10.1021/ja8049063.
   PubMed Web of Science ®Google Scholar
• Huynh K, Partch CL. Analysis of protein stability and ligand interactions by thermal shift assay. Curr Protoc Protein Sci. 2015;79:28–29. doi:10.1002/0471140864.ps2809s79.
   PubMedGoogle Scholar
• Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2:2212–2221. doi:10.1038/nprot.2007.321.
   PubMed Web of Science ®Google Scholar
• Bye JW, Platts L, Falconer RJ. Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments. Biotechnol Lett. 2014;36:869–875. doi:10.1007/s10529-013-1445-6.
   PubMed Web of Science ®Google Scholar
• Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, Alvarez JC, Volkin DB. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J Pharm Sci. 2011;100:1009–1021. doi:10.1002/jps.22350.
   PubMed Web of Science ®Google Scholar
• Garidel P, Kuhn AB, Schafer LV, Karow-Zwick AR, Blech M. High-concentration protein formulations: how high is high? Eur J Pharm Biopharm. 2017;119:353–360. doi:10.1016/j.ejpb.2017.06.029.
   PubMed Web of Science ®Google Scholar
• Trevino SR, Scholtz JM, Pace CN. Measuring and increasing protein solubility. J Pharm Sci. 2008;97:4155–4166. doi:10.1002/jps.21327.
   PubMed Web of Science ®Google Scholar
• Sormanni P, Amery L, Ekizoglou S, Vendruscolo M, Popovic B. Rapid and accurate in silico solubility screening of a monoclonal antibody library. Sci Rep. 2017;7:8200. doi:10.1038/s41598-017-07800-w.
   PubMed Web of Science ®Google Scholar
• Geng SB, Cheung JK, Narasimhan C, Shameem M, Tessier PM. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions. J Pharm Sci. 2014;103:3356–3363. doi:10.1002/jps.24130.
   PubMed Web of Science ®Google Scholar
• Garidel P. Protein solubility from a biochemical, physicochemical and colloidal perspective. Am Pharm Rev. 2013; December 30. https://www.americanpharmaceuticalreview.com/Featured-Articles/152568-Protein-Solubility-from-a-Biochemical-Physicochemical-and--Colloidal-Perspective/
   Google Scholar
• Kalonia C, Toprani V, Toth R, Wahome N, Gabel I, Middaugh CR, Volkin DB. Effects of protein conformation, apparent solubility, and protein-protein interactions on the rates and mechanisms of aggregation for an IgG1Monoclonal antibody. J Phys Chem B. 2016;120:7062–7075. doi:10.1021/acs.jpcb.6b03878.
   PubMed Web of Science ®Google Scholar
• Maurer RW, Sandler SI, Lenhoff AM. Salting-in characteristics of globular proteins. Biophys Chem. 2011;156:72–78. doi:10.1016/j.bpc.2011.02.002.
   PubMed Web of Science ®Google Scholar
• Kumar V, Sharma VK, Kalonia DS. Effect of polyols on polyethylene glycol (PEG)-induced precipitation of proteins: impact on solubility, stability and conformation. Int J Pharm. 2009;366:38–43. doi:10.1016/j.ijpharm.2008.08.037.
   PubMed Web of Science ®Google Scholar
• Li L, Kantor A, Warne N. Application of a PEG precipitation method for solubility screening: a tool for developing high protein concentration formulations. Protein Sci. 2013;22:1118–1123. doi:10.1002/pro.2289.
   PubMed Web of Science ®Google Scholar
• Toprani VM, Joshi SB, Kueltzo LA, Schwartz RM, Middaugh CR, Volkin DB. A micro-polyethylene glycol precipitation assay as a relative solubility screening tool for monoclonal antibody design and formulation development. J Pharm Sci. 2016;105:2319–2327. doi:10.1016/j.xphs.2016.05.021.
   PubMed Web of Science ®Google Scholar
• Hofmann M, Winzer M, Weber C, Gieseler H. Limitations of polyethylene glycol-induced precipitation as predictive tool for protein solubility during formulation development. J Pharm Pharmacol. 2018;70:648–654. doi:10.1111/jphp.12699.
   PubMed Web of Science ®Google Scholar
• Ruppert S, Sandler SI, Lenhoff AM. Correlation between the osmotic second virial coefficient and the solubility of proteins. Biotechnol Prog. 2001;17:182–187. doi:10.1021/bp0001314.
   PubMed Web of Science ®Google Scholar
• Valente JJ, Payne RW, Manning MC, Wilson WW, Henry CS. Colloidal behavior of proteins: effects of the second virial coefficient on solubility, crystallization and aggregation of proteins in aqueous solution. Curr Pharm Biotechnol. 2005;6:427–436.
   PubMed Web of Science ®Google Scholar
• Tessier PM, Lenhoff AM, Sandler SI. Rapid measurement of protein osmotic second virial coefficients by self-interaction chromatography. Biophys J. 2002;82:1620–1631. doi:10.1016/S0006-3495(02)75513-6.
   PubMed Web of Science ®Google Scholar
• Moon. YU, Curtis RA, Anderson CO, Blanch HW, Prausnitz JM. Protein—protein interactions in aqueous ammonium sulfate solutions. Lysozyme and Bovine Serum Albumin (BSA). J Solution Chem. 2000;29:19. doi:10.1023/A:1005112927213.
   Web of Science ®Google Scholar
• Alford JR, Kendrick BS, Carpenter JF, Randolph TW. Measurement of the second osmotic virial coefficient for protein solutions exhibiting monomer-dimer equilibrium. Anal Biochem. 2008;377:128–133. doi:10.1016/j.ab.2008.03.032.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Wilson WW, DeLucas LJ. Protein solubilization: a novel approach. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;971:99–106. doi:10.1016/j.jchromb.2014.09.003.
   PubMed Web of Science ®Google Scholar
• Velev OD, Kaler EW, Lenhoff AM. Protein interactions in solution characterized by light and neutron scattering: comparison of lysozyme and chymotrypsinogen. Biophys J. 1998;75:2682–2697. doi:10.1016/S0006-3495(98)77713-6.
   PubMed Web of Science ®Google Scholar
• Rakel N, Bauer KC, Galm L, Hubbuch J. From osmotic second virial coefficient (B22) to phase behavior of a monoclonal antibody. Biotechnol Prog. 2015;31:438–451. doi:10.1002/btpr.2065.
   PubMed Web of Science ®Google Scholar
• Rowe JB, Cancel RA, Evangelous TD, Flynn RP, Pechenov S, Subramony JA, Zhang J, Wang Y. Metastability gap in the phase diagram of monoclonal IgG antibody. Biophys J. 2017;113:1750–1756. doi:10.1016/j.bpj.2017.08.048.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Wu SJ, Feng Y, Bethea D, O’Neil KT. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates. Pharm Res. 2010;27:65–71. doi:10.1007/s11095-009-0007-z.
   PubMed Web of Science ®Google Scholar
• Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6:483–492. doi:10.4161/mabs.27431.
   PubMed Web of Science ®Google Scholar
• Baek Y, Zydney AL. Intermolecular interactions in highly concentrated formulations of recombinant therapeutic proteins. Curr Opin Biotechnol. 2017;53:59–64. doi:10.1016/j.copbio.2017.12.016.
   PubMed Web of Science ®Google Scholar
• Baek Y, Singh N, Arunkumar A, Borys M, Li ZJ, Zydney AL. Ultrafiltration behavior of monoclonal antibodies and Fc-fusion proteins: effects of physical properties. Biotechnol Bioeng. 2017;114:2057–2065. doi:10.1002/bit.26326.
   PubMed Web of Science ®Google Scholar
• Lutz H, Arias J, Zou Y. High concentration biotherapeutic formulation and ultrafiltration: part 1 pressure limits. Biotechnol Prog. 2017;33:113–124. doi:10.1002/btpr.2334.
   PubMed Web of Science ®Google Scholar
• Shieu W, Lamar D, Stauch OB, Maa YF. Filling of high-concentration monoclonal antibody formulations: investigating underlying mechanisms that affect precision of low-volume fill by peristaltic pump. PDA J Pharm Sci Technol. 2016;70:143–156. doi:10.5731/pdajpst.2015.005926.
   PubMedGoogle Scholar
• Shieu W, Torhan SA, Chan E, Hubbard A, Gikanga B, Stauch OB, Maa Y-F. Filling of high-concentration monoclonal antibody formulations into pre-filled syringes: filling parameter investigation and optimization. PDA J Pharm Sci Technol. 2014;68:153–163. doi:10.5731/pdajpst.2014.00973.
   PubMedGoogle Scholar
• Allmendinger A, Fischer S, Huwyler J, Mahler HC, Schwarb E, Zarraga IE, Mueller R. Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions. Eur J Pharm Biopharm. 2014;87:318–328. doi:10.1016/j.ejpb.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Narasimhan C, Mach H, Shameem M. High-dose monoclonal antibodies via the subcutaneous route: challenges and technical solutions, an industry perspective. Ther Deliv. 2012;3:889–900.
   PubMedGoogle Scholar
• Esfandiary R, Parupudi A, Casas-Finet J, Gadre D, Sathish H. Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions. J Pharm Sci. 2015;104:577–586. doi:10.1002/jps.24237.
   PubMed Web of Science ®Google Scholar
• Kanai S, Liu J, Patapoff TW, Shire SJ. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity. J Pharm Sci. 2008;97:4219–4227. doi:10.1002/jps.21322.
   PubMed Web of Science ®Google Scholar
• Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci. 2005;94:1928–1940. doi:10.1002/jps.20347.
   PubMed Web of Science ®Google Scholar
• Li L, Kumar S, Buck PM, Burns C, Lavoie J, Singh SK, Warne NW, Nichols P, Luksha N, Boardman D. Concentration dependent viscosity of monoclonal antibody solutions: explaining experimental behavior in terms of molecular properties. Pharm Res. 2014;31:3161–3178. doi:10.1007/s11095-014-1409-0.
   PubMed Web of Science ®Google Scholar
• Kamerzell TJ, Kanai S, Liu J, Shire SJ, Wang YJ. Increasing IgG concentration modulates the conformational heterogeneity and bonding network that influence solution properties. J Phys Chem B. 2009;113:6109–6118. doi:10.1021/jp9001548.
   PubMed Web of Science ®Google Scholar
• Guo Z, Chen A, Nassar RA, Helk B, Mueller C, Tang Y, Gupta K, Klibanov AM. Structure-activity relationship for hydrophobic salts as viscosity-lowering excipients for concentrated solutions of monoclonal antibodies. Pharm Res. 2012;29:3102–3109. doi:10.1007/s11095-012-0802-9.
   PubMed Web of Science ®Google Scholar
• He F, Woods CE, Litowski JR, Roschen LA, Gadgil HS, Razinkov VI, Kerwin BA. Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions. Pharm Res. 2011;28:1552–1560. doi:10.1007/s11095-011-0388-7.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang N, Hu T, Dai W, Feng X, Zhang X, Qian F. Viscosity-lowering effect of amino acids and salts on highly concentrated solutions of two IgG1 monoclonal antibodies. Mol Pharm. 2015;12:4478–4487. doi:10.1021/acs.molpharmaceut.5b00643.
   PubMed Web of Science ®Google Scholar
• Hong T, Iwashita K, Shiraki K. Viscosity control of protein solution by small solutes: a review. Curr Protein Pept Sci. 2018;19:746–758. doi:10.2174/1389203719666171213114919.
   PubMed Web of Science ®Google Scholar
• Neergaard MS, Kalonia DS, Parshad H, Nielsen AD, Møller EH, van de Weert M, van de Weert M. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - prediction of viscosity through protein-protein interaction measurements. Eur J Pharm Sci. 2013;49:400–410. doi:10.1016/j.ejps.2013.04.019.
   PubMed Web of Science ®Google Scholar
• Yadav S, Shire SJ, Kalonia DS. Factors affecting the viscosity in high concentration solutions of different monoclonal antibodies. J Pharm Sci. 2010;99:4812–4829. doi:10.1002/jps.22190.
   PubMed Web of Science ®Google Scholar
• He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem. 2010;399:141–143. doi:10.1016/j.ab.2009.12.003.
   PubMed Web of Science ®Google Scholar
• Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys J. 2012;103:69–78.
   PubMed Web of Science ®Google Scholar
• Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause H-J, Mahler H-C, Meyer BK, et al. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. J Pharm Sci. 2010;99:3302–3321. doi:10.1002/jps.22097.
   PubMed Web of Science ®Google Scholar
• Das TK. Protein particulate detection issues in biotherapeutics development–current status. AAPS PharmSciTech. 2012;13:732–746. doi:10.1208/s12249-012-9793-4.
   PubMed Web of Science ®Google Scholar
• Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS J. 2006;8:E564–71. doi:10.1208/aapsj080365.
   PubMed Web of Science ®Google Scholar
• Philo JS. A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol. 2009;10:359–372.
   PubMed Web of Science ®Google Scholar
• Nowak C, Ponniah G, Neill A, Liu H. Characterization of succinimide stability during trypsin digestion for LC-MS analysis. Anal Biochem. 2017;526:1–8. doi:10.1016/j.ab.2017.03.005.
   PubMed Web of Science ®Google Scholar
• Yadav S, Liu J, Shire SJ, Kalonia DS. Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci. 2010;99:1152–1168. doi:10.1002/jps.21898.
   PubMed Web of Science ®Google Scholar
• Yadav S, Shire SJ, Kalonia DS. Viscosity behavior of high-concentration monoclonal antibody solutions: correlation with interaction parameter and electroviscous effects. J Pharm Sci. 2012;101:998–1011. doi:10.1002/jps.22831.
   PubMed Web of Science ®Google Scholar
• Kayser V, Chennamsetty N, Voynov V, Helk B, Trout BL. Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding. MAbs. 2011;3:408–411.
   PubMed Web of Science ®Google Scholar
• Gaza-Bulseco G, Bulseco A, Chumsae C, Liu H. Characterization of the glycosylation state of a recombinant monoclonal antibody using weak cation exchange chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;862:155–160. doi:10.1016/j.jchromb.2007.12.001.
   PubMed Web of Science ®Google Scholar
• Ponniah G, Kita A, Nowak C, Neill A, Kori Y, Rajendran S, Liu H. Characterization of the acidic species of a monoclonal antibody using weak cation exchange chromatography and LC-MS. Anal Chem. 2015;87:9084–9092. doi:10.1021/acs.analchem.5b02385.
   PubMed Web of Science ®Google Scholar
• Chumsae C, Gaza-Bulseco G, Sun J, Liu H. Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;850:285–294. doi:10.1016/j.jchromb.2006.11.050.
   PubMed Web of Science ®Google Scholar
• Teshima G, Li M-X, Danishmand R, Obi C, To R, Huang C, Kung J, Lahidji V, Freeberg J, Thorner L, et al. Separation of oxidized variants of a monoclonal antibody by anion-exchange. J Chromatogr A. 2011;1218:2091–2097. doi:10.1016/j.chroma.2010.10.107.
   PubMed Web of Science ®Google Scholar
• Perkins M, Theiler R, Lunte S, Jeschke M. Determination of the origin of charge heterogeneity in a murine monoclonal antibody. Pharm Res. 2000;17:1110–1117.
   PubMed Web of Science ®Google Scholar
• Zhang W, Czupryn MJ. Analysis of isoaspartate in a recombinant monoclonal antibody and its charge isoforms. J Pharm Biomed Anal. 2003;30:1479–1490.
   PubMed Web of Science ®Google Scholar
• Gandhi S, Ren D, Xiao G, Bondarenko P, Sloey C, Ricci MS, Krishnan S. Elucidation of degradants in acidic peak of cation exchange chromatography in an IgG1 monoclonal antibody formed on long-term storage in a liquid formulation. Pharm Res. 2012;29:209–224. doi:10.1007/s11095-011-0536-0.
   PubMed Web of Science ®Google Scholar
• King C, Patel R, Ponniah G, Nowak C, Neill A, Gu Z, Liu H. Characterization of recombinant monoclonal antibody variants detected by hydrophobic interaction chromatography and imaged capillary isoelectric focusing electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci. 2018;1085:96–103. doi:10.1016/j.jchromb.2018.03.049.
   PubMed Web of Science ®Google Scholar
• Santora LC, Krull IS, Grant K. Characterization of recombinant human monoclonal tissue necrosis factor-alpha antibody using cation-exchange HPLC and capillary isoelectric focusing. Anal Biochem. 1999;275:98–108. doi:10.1006/abio.1999.4275.
   PubMed Web of Science ®Google Scholar
• Zhang T, Bourret J, Cano T. Isolation and characterization of therapeutic antibody charge variants using cation exchange displacement chromatography. J Chromatogr A. 2011;1218:5079–5086. doi:10.1016/j.chroma.2011.05.061.
   PubMed Web of Science ®Google Scholar
• Alvarez M, Tremintin G, Wang J, Eng M, Kao Y-H, Jeong J, Ling VT, Borisov OV. On-line characterization of monoclonal antibody variants by liquid chromatography-mass spectrometry operating in a two-dimensional format. Anal Biochem. 2011;419:17–25. doi:10.1016/j.ab.2011.07.033.
   PubMed Web of Science ®Google Scholar
• Ponniah G, Nowak C, Neill A, Liu H. Characterization of charge variants of a monoclonal antibody using weak anion exchange chromatography at subunit levels. Anal Biochem. 2017;520:49–57. doi:10.1016/j.ab.2016.12.017.
   PubMed Web of Science ®Google Scholar
• Liu H, Ren W, Zong L, Zhang J, Wang Y. Characterization of recombinant monoclonal antibody charge variants using WCX chromatography, icIEF and LC-MS/MS. Anal Biochem. 2019;564-565:1–12. doi:10.1016/j.ab.2018.10.002.
   PubMed Web of Science ®Google Scholar
• Tsai PK, Bruner MW, Irwin JI, Ip CC, Oliver CN, Nelson RW, Volkin DB, Middaugh CR. Origin of the isoelectric heterogeneity of monoclonal immunoglobulin h1B4. Pharm Res. 1993;10:1580–1586.
   PubMed Web of Science ®Google Scholar
• Ma S, Nashabeh W. Analysis of protein therapeutics by capillary electrophoresis. Chromatographia. 2001;122:s75–s89.
   Google Scholar
• Ma S. Analysis of protein therapeutics by capillary electrophoresis: applications and challenges. Dev Biol (Basel). 2005;122:49–68.
   PubMedGoogle Scholar
• Janini G, Saptharishi N, Waselus M, Soman G. Element of a validation method for MU-B3 monoclonal antibody using an imaging capillary isoelectric focusing system. Electrophoresis. 2002;23:1605–1611. doi:10.1002/1522-2683(200206)23:11<1605::AID-ELPS1605>3.0.CO;2-O.
   PubMed Web of Science ®Google Scholar
• Li N, Kessler K, Bass L, Zeng D. Evaluation of the iCE280 Analyzer as a potential high-throughput tool for formulation development. J Pharm Biomed Anal. 2007;43:963–972. doi:10.1016/j.jpba.2006.09.024.
   PubMed Web of Science ®Google Scholar
• He XZ, Que AH, Mo JJ. Analysis of charge heterogeneities in mAbs using imaged CE. Electrophoresis. 2009;30:714–722. doi:10.1002/elps.200800636.
   PubMed Web of Science ®Google Scholar
• Wu J, Pawliszyn J. Dual detection for capillary isoelectric focusing with refractive index gradient and absorption imaging detectors. Anal Chem. 1994;66:6. doi:10.1021/ac00078a018.
   Web of Science ®Google Scholar
• He Y, Isele C, Hou W, Ruesch M. Rapid analysis of charge variants of monoclonal antibodies with capillary zone electrophoresis in dynamically coated fused-silica capillary. J Sep Sci. 2011;34:548–555. doi:10.1002/jssc.201000719.
   PubMed Web of Science ®Google Scholar
• Shi Y, Li Z, Qiao Y, Lin J. Development and validation of a rapid capillary zone electrophoresis method for determining charge variants of mAb. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;906:63–68. doi:10.1016/j.jchromb.2012.08.022.
   PubMed Web of Science ®Google Scholar
• Espinosa-de la Garza CE, Perdomo-Abundez FC, Padilla-Calderon J, Uribe-Wiechers JM, Perez NO, Flores-Ortiz LF, Medina-Rivero E. Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis. Electrophoresis. 2013;34:1133–1140. doi:10.1002/elps.201200575.
   PubMed Web of Science ®Google Scholar
• He Y, Lacher NA, Hou W, Wang Q, Isele C, Starkey J, Ruesch M. Analysis of identity, charge variants, and disulfide isomers of monoclonal antibodies with capillary zone electrophoresis in an uncoated capillary column. Anal Chem. 2010;82:3222–3230. doi:10.1021/ac9028856.
   PubMed Web of Science ®Google Scholar
• Gahoual R, Beck A, Francois YN, Leize-Wagner E. Independent highly sensitive characterization of asparagine deamidation and aspartic acid isomerization by sheathless CZE-ESI-MS/MS. J Mass Spectrom. 2016;51:150–158. doi:10.1002/jms.3735.
   PubMed Web of Science ®Google Scholar
• Gahoual R, Busnel JM, Beck A, Francois YN, Leize-Wagner E. Full antibody primary structure and microvariant characterization in a single injection using transient isotachophoresis and sheathless capillary electrophoresis-tandem mass spectrometry. Anal Chem. 2014;86:9074–9081. doi:10.1021/ac502378e.
   PubMed Web of Science ®Google Scholar
• Farnan D, Moreno GT. Multiproduct high-resolution monoclonal antibody charge variant separations by pH gradient ion-exchange chromatography. Anal Chem. 2009;81:8846–8857. doi:10.1021/ac901408j.
   PubMed Web of Science ®Google Scholar
• Wagner-Rousset E, Fekete S, Morel-Chevillet L, Colas O, Corvaia N, Cianferani S, Guillarme D, Beck A. Development of a fast workflow to screen the charge variants of therapeutic antibodies. J Chromatogr A. 2017;1498:147–154. doi:10.1016/j.chroma.2017.02.065.
   PubMed Web of Science ®Google Scholar
• Joshi V, Kumar V, Rathore AS. Rapid analysis of charge variants of monoclonal antibodies using non-linear salt gradient in cation-exchange high performance liquid chromatography. J Chromatogr A. 2015;1406:175–185. doi:10.1016/j.chroma.2015.06.015.
   PubMed Web of Science ®Google Scholar
• Haverick M, Mengisen S, Shameem M, Ambrogelly A. Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications. MAbs. 2014;6:852–858.
   PubMed Web of Science ®Google Scholar
• Kohli N, Jain N, Geddie ML, Razlog M, Xu L, Lugovskoy AA. A novel screening method to assess developability of antibody-like molecules. MAbs. 2015;7:752–758. doi:10.1080/19420862.2015.1048410.
   PubMed Web of Science ®Google Scholar
• Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010;114:6614–6624. doi:10.1021/jp911706q.
   PubMed Web of Science ®Google Scholar
• Estep P, Caffry I, Yu Y, Sun T, Cao Y, Lynaugh H, Jain T, Vásquez M, Tessier PM, Xu Y. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies. MAbs. 2015;7:553–561. doi:10.1080/19420862.2015.1016694.
   PubMed Web of Science ®Google Scholar
• Boyd D, Kaschak T, Yan B. HIC resolution of an IgG1 with an oxidized Trp in a complementarity determining region. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:955–960. doi:10.1016/j.jchromb.2011.03.006.
   PubMed Web of Science ®Google Scholar
• Chaderjian WB, Chin ET, Harris RJ, Etcheverry TM. Effect of copper sulfate on performance of a serum-free CHO cell culture process and the level of free thiol in the recombinant antibody expressed. Biotechnol Prog. 2005;21:550–553. doi:10.1021/bp0497029.
   PubMed Web of Science ®Google Scholar
• Lacy ER, Baker M, Brigham-Burke M. Free sulfhydryl measurement as an indicator of antibody stability. Anal Biochem. 2008;382:66–68. doi:10.1016/j.ab.2008.07.016.
   PubMed Web of Science ®Google Scholar
• Chumsae C, Gaza-Bulseco G, Liu H. Identification and localization of unpaired cysteine residues in monoclonal antibodies by fluorescence labeling and mass spectrometry. Anal Chem. 2009;81:6449–6457. doi:10.1021/ac900815z.
   PubMed Web of Science ®Google Scholar
• Xiang T, Chumsae C, Liu H. Localization and quantitation of free sulfhydryl in recombinant monoclonal antibodies by differential labeling with 12C and 13C iodoacetic acid and LC-MS analysis. Anal Chem. 2009;81:8101–8108. doi:10.1021/ac901311y.
   PubMed Web of Science ®Google Scholar
• Brych SR, Gokarn YR, Hultgen H, Stevenson RJ, Rajan R, Matsumura M. Characterization of antibody aggregation: role of buried, unpaired cysteines in particle formation. J Pharm Sci. 2010;99:764–781. doi:10.1002/jps.21868.
   PubMed Web of Science ®Google Scholar
• Huh JH, White AJ, Brych SR, Franey H, Matsumura M. The identification of free cysteine residues within antibodies and a potential role for free cysteine residues in covalent aggregation because of agitation stress. J Pharm Sci. 2013;102:1701–1711. doi:10.1002/jps.23505.
   PubMed Web of Science ®Google Scholar
• Lilyestrom WG, Yadav S, Shire SJ, Scherer TM. Monoclonal antibody self-association, cluster formation, and rheology at high concentrations. J Phys Chem B. 2013;117:6373–6384. doi:10.1021/jp4008152.
   PubMed Web of Science ®Google Scholar
• Arora J, Hu Y, Esfandiary R, Sathish HA, Bishop SM, Joshi SB, Middaugh CR, Volkin DB, Weis DD. Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity. MAbs. 2016;8:1561–1574. doi:10.1080/19420862.2016.1222342.
   PubMed Web of Science ®Google Scholar
• Singh SN, Yadav S, Shire SJ, Kalonia DS. Dipole-dipole interaction in antibody solutions: correlation with viscosity behavior at high concentration. Pharm Res. 2014;31:2549–2558. doi:10.1007/s11095-014-1352-0.
   PubMed Web of Science ®Google Scholar
• Bumbaca D, Wong A, Drake E, Reyes AE 2nd, Lin BC, Stephan J-P, Desnoyers L, Shen B-Q, Dennis MS. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs. 2011;3:376–386.
   PubMed Web of Science ®Google Scholar
• Nishi H, Miyajima M, Wakiyama N, Kubota K, Hasegawa J, Uchiyama S, Fukui K. Fc domain mediated self-association of an IgG1 monoclonal antibody under a low ionic strength condition. J Biosci Bioeng. 2011;112:326–332. doi:10.1016/j.jbiosc.2011.06.017.
   PubMed Web of Science ®Google Scholar
• Sun T, Reid F, Liu Y, Cao Y, Estep P, Nauman C, Xu Y. High throughput detection of antibody self-interaction by bio-layer interferometry. MAbs. 2013;5:838–841. doi:10.4161/mabs.26186.
   PubMed Web of Science ®Google Scholar
• Sule SV, Dickinson CD, Lu J, Chow CK, Tessier PM. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates. Mol Pharm. 2013;10:1322–1331. doi:10.1021/mp300524x.
   PubMed Web of Science ®Google Scholar
• Sule SV, Sukumar M, Weiss W, Marcelino-Cruz AM, Sample T, Tessier PM. High-throughput analysis of concentration-dependent antibody self-association. Biophys J. 2011;101:1749–1757. doi:10.1016/j.bpj.2011.08.036.
   PubMed Web of Science ®Google Scholar
• Tessier PM, Sandler SI, Lenhoff AM. Direct measurement of protein osmotic second virial cross coefficients by cross-interaction chromatography. Protein Sci. 2004;13:1379–1390. doi:10.1110/ps.03419204.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu T-Y, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26:663–670. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Datta-Mannan A, Chow CK, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys. Drug Metab Dispos. 2012;40:1545–1555. doi:10.1124/dmd.112.045864.
   PubMed Web of Science ®Google Scholar
• Hotzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4:753–760. doi:10.4161/mabs.22189.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Geoghegan JC, Feldman J, Jain T, Kauke M, Le D, Zhao J, Wittrup KD. Chaperone proteins as single component reagents to assess antibody nonspecificity. MAbs. 2017;9:1036–1040. doi:10.1080/19420862.2017.1356529.
   PubMed Web of Science ®Google Scholar
• Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs. 2015;7:770–777. doi:10.1080/19420862.2015.1043503.
   PubMed Web of Science ®Google Scholar
• Alexander AJ, Hughes DE. Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry. Anal Chem. 1995;67:3626–3632.
   PubMed Web of Science ®Google Scholar
• Andya JD, Maa YF, Costantino HR, Nguyen PA, Dasovich N, Sweeney TD, Hsu CC, Shire SJ. The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm Res. 1999;16:350–358.
   PubMed Web of Science ®Google Scholar
• Fesinmeyer RM, Hogan S, Saluja A, Brych SR, Kras E, Narhi LO, Brems DN, Gokarn YR. Effect of ions on agitation- and temperature-induced aggregation reactions of antibodies. Pharm Res. 2009;26:903–913. doi:10.1007/s11095-008-9792-z.
   PubMed Web of Science ®Google Scholar
• Franey H, Brych SR, Kolvenbach CG, Rajan RS. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci. 2010;19:1601–1615. doi:10.1002/pro.434.
   PubMed Web of Science ®Google Scholar
• Hawe A, Kasper JC, Friess W, Jiskoot W. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci. 2009;38:79–87. doi:10.1016/j.ejps.2009.06.001.
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Beuvery EC, de Koning AA, Herron JN, Crommelin DJ. Analytical approaches to the study of monoclonal antibody stability. Pharm Res. 1990;7:1234–1241.
   PubMed Web of Science ®Google Scholar
• Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. Classification and characterization of therapeutic antibody aggregates. J Biol Chem. 2011;286:25118–25133. doi:10.1074/jbc.M110.160457.
   PubMed Web of Science ®Google Scholar
• Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem. 2011;286:25134–25144. doi:10.1074/jbc.M110.160440.
   PubMed Web of Science ®Google Scholar
• Telikepalli SN, Kumru OS, Kalonia C, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci. 2014;103:796–809. doi:10.1002/jps.23839.
   PubMed Web of Science ®Google Scholar
• Van Buren N, Rehder D, Gadgil H, Matsumura M, Jacob J. Elucidation of two major aggregation pathways in an IgG2 antibody. J Pharm Sci. 2009;98:3013–3030. doi:10.1002/jps.21514.
   PubMed Web of Science ®Google Scholar
• Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res. 2012;29:236–250. doi:10.1007/s11095-011-0538-y.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Lundell E. Assessment of antibody fragmentation by reversed-phase liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876:13–23. doi:10.1016/j.jchromb.2008.10.015.
   PubMed Web of Science ®Google Scholar
• Dillon TM, Bondarenko PV, Rehder DS, Pipes GD, Kleemann GR, Ricci MS. Optimization of a reversed-phase high-performance liquid chromatography/mass spectrometry method for characterizing recombinant antibody heterogeneity and stability. J Chromatogr A. 2006;1120:112–120. doi:10.1016/j.chroma.2006.01.016.
   PubMed Web of Science ®Google Scholar
• Cordoba AJ, Shyong BJ, Breen D, Harris RJ. Non-enzymatic hinge region fragmentation of antibodies in solution. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;818:115–121. doi:10.1016/j.jchromb.2004.12.033.
   PubMed Web of Science ®Google Scholar
• Dillon TM, Bondarenko PV, Speed Ricci M. Development of an analytical reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry method for characterization of recombinant antibodies. J Chromatogr A. 2004;1053:299–305.
   PubMed Web of Science ®Google Scholar
• Gaza-Bulseco G, Liu H. Fragmentation of a recombinant monoclonal antibody at various pH. Pharm Res. 2008;25:1881–1890. doi:10.1007/s11095-008-9606-3.
   PubMed Web of Science ®Google Scholar
• Xiang T, Lundell E, Sun Z, Liu H. Structural effect of a recombinant monoclonal antibody on hinge region peptide bond hydrolysis. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858:254–262. doi:10.1016/j.jchromb.2007.08.043.
   PubMed Web of Science ®Google Scholar
• Kroon DJ, Baldwin-Ferro A, Lalan P. Identification of sites of degradation in a therapeutic monoclonal antibody by peptide mapping. Pharm Res. 1992;9:1386–1393.
   PubMed Web of Science ®Google Scholar
• Zhang YT, Hu J, Pace AL, Wong R, Wang YJ, Kao YH. Characterization of asparagine 330 deamidation in an Fc-fragment of IgG1 using cation exchange chromatography and peptide mapping. J Chromatogr B Analyt Technol Biomed Life Sci. 2014;965:65–71. doi:10.1016/j.jchromb.2014.06.018.
   PubMed Web of Science ®Google Scholar
• Paborji M, Pochopin NL, Coppola WP, Bogardus JB. Chemical and physical stability of chimeric L6, a mouse-human monoclonal antibody. Pharm Res. 1994;11:764–771.
   PubMed Web of Science ®Google Scholar
• Cohen SL, Price C, Vlasak J. Beta-elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J Am Chem Soc. 2007;129:6976–6977. doi:10.1021/ja0705994.
   PubMed Web of Science ®Google Scholar
• Arosio P, Rima S, Morbidelli M. Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates. Pharm Res. 2013;30:641–654. doi:10.1007/s11095-012-0885-3.
   PubMed Web of Science ®Google Scholar
• Sharma DK, Oma P, Pollo MJ, Sukumar M. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. J Pharm Sci. 2010;99:2628–2642. doi:10.1002/jps.22046.
   PubMed Web of Science ®Google Scholar
• Ghazvini S, Kalonia C, Volkin DB, Dhar P. Evaluating the role of the air-solution interface on the mechanism of subvisible particle formation caused by mechanical agitation for an IgG1 mAb. J Pharm Sci. 2016;105:1643–1656. doi:10.1016/j.xphs.2016.02.027.
   PubMed Web of Science ®Google Scholar
• Kiese S, Papppenberger A, Friess W, Mahler HC. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci. 2008;97:4347–4366. doi:10.1002/jps.21328.
   PubMed Web of Science ®Google Scholar
• Mahler HC, Muller R, Friess W, Delille A, Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur J Pharm Biopharm. 2005;59:407–417. doi:10.1016/j.ejpb.2004.12.004.
   PubMed Web of Science ®Google Scholar
• Serno T, Carpenter JF, Randolph TW, Winter G. Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-cyclodextrin. J Pharm Sci. 2010;99:1193–1206. doi:10.1002/jps.21931.
   PubMed Web of Science ®Google Scholar
• Eppler A, Weigandt M, Hanefeld A, Bunjes H. Relevant shaking stress conditions for antibody preformulation development. Eur J Pharm Biopharm. 2010;74:139–147. doi:10.1016/j.ejpb.2009.11.005.
   PubMed Web of Science ®Google Scholar
• Kueltzo LA, Wang W, Randolph TW, Carpenter JF. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci. 2008;97:1801–1812. doi:10.1002/jps.21110.
   PubMed Web of Science ®Google Scholar
• Singh SR, Zhang J, O’Dell C, Hsieh MC, Goldstein J, Liu J, Srivastava A. Effect of polysorbate 80 quality on photostability of a monoclonal antibody. AAPS PharmSciTech. 2012;13:422–430. doi:10.1208/s12249-012-9759-6.
   PubMed Web of Science ®Google Scholar
• Nowak C, Ponniah G, Cheng G, Kita A, Neill A, Kori Y, Liu H. Liquid chromatography-fluorescence and liquid chromatography-mass spectrometry detection of tryptophan degradation products of a recombinant monoclonal antibody. Anal Biochem. 2016;496:4–8. doi:10.1016/j.ab.2015.12.004.
   PubMed Web of Science ®Google Scholar
• Liu H, Gaza-Bulseco G, Zhou L. Mass spectrometry analysis of photo-induced methionine oxidation of a recombinant human monoclonal antibody. J Am Soc Mass Spectrom. 2009;20:525–528. doi:10.1016/j.jasms.2008.11.011.
   PubMed Web of Science ®Google Scholar
• Chaudhri A, Zarraga IE, Kamerzell TJ, Brandt JP, Patapoff TW, Shire SJ, Voth GA. Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies. J Phys Chem B. 2012;116:8045–8057. doi:10.1021/jp301140u.
   PubMed Web of Science ®Google Scholar
• Ali SA, Hassan MI, Islam A, Ahmad F. A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states. Curr Protein Pept Sci. 2014;15:456–476.
   PubMed Web of Science ®Google Scholar
• Agrawal NJ, Helk B, Kumar S, Mody N, Sathish HA, Samra HS, Buck PM, Li L, Trout BL. Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs. 2016;8:43–48. doi:10.1080/19420862.2015.1099773.
   PubMed Web of Science ®Google Scholar
• Buck PM, Chaudhri A, Kumar S, Singh SK. Highly viscous antibody solutions are a consequence of network formation caused by domain-domain electrostatic complementarities: insights from coarse-grained simulations. Mol Pharm. 2015;12:127–139. doi:10.1021/mp500485w.
   PubMed Web of Science ®Google Scholar
• Chaudhri A, Zarraga IE, Yadav S, Patapoff TW, Shire SJ, Voth GA. The role of amino acid sequence in the self-association of therapeutic monoclonal antibodies: insights from coarse-grained modeling. J Phys Chem B. 2013;117:1269–1279. doi:10.1021/jp3108396.
   PubMed Web of Science ®Google Scholar
• Obrezanova O, Arnell A, de la Cuesta RG, Berthelot ME, Gallagher TRA, Zurdo J, Stallwood Y. Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs. 2015;7:352–363. doi:10.1080/19420862.2015.1007828.
   PubMed Web of Science ®Google Scholar
• Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I. Immunogenicity screening in protein drug development. Expert Opin Biol Ther. 2007;7:405–418. doi:10.1517/14712598.7.3.405.
   PubMed Web of Science ®Google Scholar
• Bumbaca Yadav D, Sharma VK, Boswell CA, Hotzel I, Tesar D, Shang Y, Ying Y, Fischer SK, Grogan JL, Chiang EY, et al. Evaluating the use of antibody variable region (Fv) charge as a risk assessment tool for predicting typical cynomolgus monkey pharmacokinetics. J Biol Chem. 2015;290:29732–29741. doi:10.1074/jbc.M115.692434.
   PubMed Web of Science ®Google Scholar
• D’Atri V, Fekete S, Beck A, Lauber M, Guillarme D. Hydrophilic interaction chromatography hyphenated with mass spectrometry: a powerful analytical tool for the comparison of originator and biosimilar therapeutic monoclonal antibodies at the middle-up level of analysis. Anal Chem. 2017;89:2086–2092. doi:10.1021/acs.analchem.6b04726.
   PubMed Web of Science ®Google Scholar
• Periat A, Fekete S, Cusumano A, Veuthey JL, Beck A, Lauber M, Guillarme D. Potential of hydrophilic interaction chromatography for the analytical characterization of protein biopharmaceuticals. J Chromatogr A. 2016;1448:81–92. doi:10.1016/j.chroma.2016.04.056.
   PubMed Web of Science ®Google Scholar
• Sorensen M, Harmes DC, Stoll DR, Staples GO, Fekete S, Guillarme D, Beck A. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry. MAbs. 2016;8:1224–1234. doi:10.1080/19420862.2016.1203497.
   PubMed Web of Science ®Google Scholar
• Stoll D, Danforth J, Zhang K, Beck A. Characterization of therapeutic antibodies and related products by two-dimensional liquid chromatography coupled with UV absorbance and mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1032:51–60. doi:10.1016/j.jchromb.2016.05.029.
   PubMed Web of Science ®Google Scholar
• Stoll DR, Harmes DC, Danforth J, Wagner E, Guillarme D, Fekete S, Beck A. Direct identification of rituximab main isoforms and subunit analysis by online selective comprehensive two-dimensional liquid chromatography-mass spectrometry. Anal Chem. 2015;87:8307–8315. doi:10.1021/acs.analchem.5b01578.
   PubMed Web of Science ®Google Scholar